NCT01395875 - Outcomes for Chronic Obstructive Pulmonary Disease Moderate Exacerbators Initiating Treatment | Biotech Hunter

Enrollment

2,849

Participants

Timeline

Start Date

March 31, 2011

Primary Completion Date

April 30, 2011

Study Completion Date

June 30, 2011

Conditions

Pulmonary Disease, Chronic Obstructive

Interventions

DRUG

Fluticasone Propionate / Salmeterol Xinafoate Combination (FSC)

COPD patients receiving fluticasone propionate/salmeterol xinafoate combination (FSC) 250/50mcg

DRUG

Anticholinergics (AC)

COPD patients receiving anticholinergics (ACs) including tiotropium (TIO) and ipratropium or combination ipratropium-albuterol (collectively referred to as ipratropium \[IPR\]).